# A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer

> **NCT05712174** · PHASE2 · TERMINATED · sponsor: **AHS Cancer Control Alberta** · enrollment: 176 (actual)

## Conditions studied

- Oncology
- Prostate Cancer

## Interventions

- **DRUG:** [18]F-PSMA-1007

## Key facts

- **NCT ID:** NCT05712174
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-14
- **Primary completion:** 2025-05-05
- **Final completion:** 2025-05-05
- **Target enrollment:** 176 (ACTUAL)
- **Why stopped:** Accrual to the biochemically recurrent and metastatic cohorts complete; however, accrual to the remaining two cohorts was lagging and deemed no longer feasible.
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05712174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05712174, "A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05712174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*